Review Article
Meta-Analysis of the Relationship between NM23 Expression to Gastric Cancer Risk and Clinical Features
Table 1
Main characteristics of the eligible studies.
| | Author | Year | Country | Cohort | Stage | Methods | 5-year OS rate | | NM23+ | NM23− |
| | Wang | 2016 | China | 230 | NA | IHC | NA | | Radovic | 2013 | Croatia | 56 | I–IV | IHC | NA | | Okayama | 2009 | Japan | 135 | I–III | IHC | NA | | Yang | 2008 | China | 40 | I–IV | IHC | NA | | Mönig | 2007 | Germany | 116 | I–IV | IHC | 35.80% | 40.00% | | Guan-Zhen | 2007 | China | 71 | I–IV | IHC | NA | | Ding | 2006 | China | 78 | I–IV | ISH | 53.70% | 4.17% | | Yu | 2006 | China | 74 | NA | IHC | NA | | Liu | 2005 | China | 40 | II/III | ISH | NA | | Chen | 2005 | China | 43 | I–IV | IHC | NA | | Chen | 2004 | China | 43 | I–IV | IHC | NA | | Li | 2003 | China | 110 | I–IV | IHC | 70.50% | 20.00% | | Lee | 2003 | Korea | 841 | I–IV | IHC | 64.50% | 79.70% | | Terada | 2002 | Japan | 103 | NA | IHC | 63.26% | 48.44% | | Ji | 2002 | China | 71 | I–IV | IHC | NA | | Wang | 1999 | China | 97 | NA | IHC | NA | | Hsu | 1999 | China | 24 | III | IHC | 31.57% | 6.90% | | Dhar | 1999 | Japan | 59 | I–IV | IHC | 11.96% | 54.06% | | Yoo | 1999 | Korea | 261 | II-III | IHC | 59.82% | 53.70% | | Wang | 1998 | China | 37 | NA | IHC | NA | | Yeung | 1998 | Australia | 23 | NA | IHC | NA | | Muller | 1998 | Germany | 529 | NA | IHC | NA | | Wei | 1997 | China | 138 | I–IV | IHC | NA | | Songun | 1996 | Holland | 105 | I–IV | IHC | NA | | Ura | 1996 | Japan | 110 | NA | IHC | 77.50% | 41.50% | | Kim | 1995 | Korea | 101 | NA | IHC | NA | | Zhang | 1995 | China | 88 | I–IV | IHC | NA |
|
|
NA, not available; OS, overall survival; IHC, immunohistochemistry; ISH, in situ hybridization.
|
